Demographics, mechanism of injury, admission physiology, and injury severity of patients on novel oral anticoagulants
| Dabigatran | Rivaroxaban | Apixaban | Pvalues | |
| n | 50 | 123 | 34 | |
| Age (SD) | 79 (12) | 74 (16) | 80 (11) | 0.137 |
| Female (%) | 52 | 46 | 56 | 0.493 |
| Renal failure (%) | 0 (0) | 1 (1) | 0 (0) | 0.710 |
| Cirrhosis (%) | 1 (2) | 2 (2) | 0 (0) | 0.729 |
| Race* (%) | 0.777 | |||
| Black | 0 | 1 | 0 | |
| Asian | 2 | 1 | 0 | |
| Hispanic | 8 | 7 | 3 | |
| Non-Hispanic white | 84 | 86 | 97 | |
| Mechanism (%) | 0.843 | |||
| Fall | 70 | 74 | 74 | |
| Motor vehicle accident | 14 | 16 | 18 | |
| Found down | 6 | 2 | 0 | |
| Auto vs. pedestrian | 4 | 2 | 0 | |
| GCS≤8 (%) | 4 | 4 | 3 | 0.954 |
| Shock (SBP<90) (%) | 4 | 7 | 0 | 0.279 |
| ISS median (IQR)† | 9 (4–13) | 5 (4–10) | 6 (4–10) | 0.834 |
| ISS≥10† (%) | 42 | 36 | 41 | 0.737 |
| Reversed (%) | 7 (14) | 31 (25) | 6 (18) | 0.225 |
Missing data <1% unless specifically noted in the table. Data previously presented.22
For Renal Failure and Cirrhosis both the number of patients as well as percent (in parentheses) of the population with the comorbidity are presented.
Values in bold signify number of patients and percent of population in parentheses.
*Race: missing/other: 9 (4%).
†ISS: missing 3 (1.5%).
GCS, Glasgow Coma Scale; ISS, Injury Severity Score; SBP, systolic blood pressure.